Hyperphosphatasia with Intellectual Disability Syndrome: Causes and Clinical Features

Hyperphosphatasia with Intellectual Disability Syndrome

Hyperphosphatasia with intellectual disability syndrome is a rare genetic condition characterized by elevated levels of alkaline phosphatase (ALP) in the blood, alongside significant neurological and developmental challenges. Historically referred to in some literature as Mabry syndrome, this group of disorders involves defects in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors, which are essential for attaching various proteins to the surface of cells.

When these anchors are not formed correctly, it disrupts cellular communication and function, particularly within the central nervous system, leading to the clinical manifestations observed in affected individuals.

[ไม่มีภาพประกอบ]

Key Facts

  • Primary Marker: Characterized by hyperphosphatasia, which is an abnormally high level of alkaline phosphatase in the serum.
  • Genetic Drivers: Linked to mutations in genes such as PIGO and PIGV.
  • Neurological Impact: Commonly presents with intellectual disability, seizures, and neurologic deficits.
  • Physical Traits: May include characteristic facial features and brachytelephalangy (shortening of the distal phalanges of the fingers and toes).
  • Biological Mechanism: Caused by defects in the biosynthesis of GPI anchors, which are necessary for protein attachment to cell membranes.

Genetic Foundations and Molecular Causes

The syndrome is rooted in the failure of the body to properly synthesize glycosylphosphatidylinositol (GPI). GPI anchors are complex glycolipids that serve as the "tethers" for a wide array of proteins on the cell surface. These proteins are critical for signal transduction, cell adhesion, and immune response.

The Role of PIGO and PIGV Mutations

Recent research has identified specific genetic mutations that drive this syndrome. Mutations in the PIGO gene have been documented in case reports of hyperphosphatasia with intellectual disability syndrome 2. Similarly, PIGV mutations have been identified through exome sequence data filtering, highlighting the gene's role in transferring mannose during the GPI synthesis process.

When these genes mutate, the resulting GPI-anchor deficiency leads to hippocampal synaptic dysfunctions, which contribute to the cognitive impairments seen in patients.

Clinical Presentation and Diagnosis

The clinical manifestation of the syndrome can vary, but several recurring patterns help clinicians identify the disorder.

Neurological and Developmental Symptoms

Intellectual disability is a hallmark of the condition. Many patients experience seizures, some of which have been noted as potentially responsive to pyridoxine. General neurologic deficits are common, often appearing in early childhood or toddlerhood, creating significant diagnostic challenges for pediatricians.

Physical and Morphological Features

Beyond neurological issues, patients may exhibit a distinct facial gestalt (a characteristic facial appearance). A specific physical marker often noted is brachytelephalangy, where the ends of the fingers and toes are abnormally short.

[ไม่มีภาพประกอบ]

Summary of Clinical and Genetic Markers

Overview of Hyperphosphatasia with Intellectual Disability Syndrome
Feature Description
Biochemical Marker Elevated serum alkaline phosphatase (Hyperphosphatasia)
Associated Genes PIGO, PIGV
Neurological Signs Intellectual disability, seizures, synaptic dysfunction
Physical Signs Brachytelephalangy, characteristic facial features
Pathophysiology GPI-anchor deficiency / Biosynthesis defects

Frequently Asked Questions

What is hyperphosphatasia?

Hyperphosphatasia refers to an abnormally high level of alkaline phosphatase (ALP) in the blood. In the context of this syndrome, it serves as a key biochemical marker that helps clinicians narrow down the genetic cause of intellectual disability.

What are GPI anchors?

Glycosylphosphatidylinositol (GPI) anchors are glycolipids that attach proteins to the external surface of the cell membrane. They are essential for the proper functioning of various cell-surface proteins.

Is this condition the same as Mabry syndrome?

Yes, historically, the combination of hyperphosphatasia, seizures, and intellectual disability was described as Mabry syndrome. Modern genetics has since refined this into specific syndromes based on the underlying gene mutation (e.g., PIGO or PIGV).

What is brachytelephalangy?

Brachytelephalangy is a physical characteristic where the distal phalanges (the bones at the very tips of the fingers and toes) are shortened.

How is the syndrome diagnosed?

Diagnosis typically involves blood tests to detect elevated alkaline phosphatase, clinical evaluation of neurological and physical features, and genetic testing (such as exome sequencing) to identify mutations in genes like PIGO or PIGV.

References

  1. Wang, Xinyi; Zhao, Jingya; Zhao, Xiaoke; Ding, Le; Zhu, Min; Li, Yang (2025). "Two case reports and a literature review of hyperphosphatasia with intellectual disability syndrome 2 caused by a PIGO mutation". Frontiers in Pediatrics. 13 1667477. doi:10.3389/fped.2025.1667477. PMC 12570174. PMID 41169893.
  2. Panda, Prateek Kumar; Palayullakandi, Achanya; Gupta, Diksha; Sopanam, Suthiraj; Kaur, Amanjot; Deo, Vijay Kumar; Kumar, Sachin; Sharawat, Indar Kumar (2025). "Hyperphosphatasia with Impaired Intellectual Development Syndrome in a Toddler: Diagnostic Challenges and Therapeutic Approach". Indian Journal of Pediatrics. 92 (3): 311. doi:10.1007/s12098-024-05372-y. PMID 39714758.
  3. Mabry CC, Bautista A, Kirk RF, Dubilier LD, Braunstein H, Koepke JA (July 1970). "Familial hyperphosphatase with mental retardation, seizures, and neurologic deficits". The Journal of Pediatrics. 77 (1): 74–85. doi:10.1016/s0022-3476(70)80047-6. PMID 5465362.
  4. Thompson MD, Nezarati MM, Gillessen-Kaesbach G, Meinecke P, Mendoza-Londono R, Mendoza R, et al. (July 2010). "Hyperphosphatasia with seizures, neurologic deficit, and characteristic facial features: Five new patients with Mabry syndrome". American Journal of Medical Genetics. Part A. 152A (7): 1661–1669. doi:10.1002/ajmg.a.33438. PMID 20578257. S2CID 2806832.
  5. Thompson MD, Killoran A, Percy ME, Nezarati M, Cole DE, Hwang PA (2006). "Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder?". Pediatric Neurology. 34 (4): 303–307. doi:10.1016/j.pediatrneurol.2005.08.020. PMID 16638507.